IDEXX LABORATORIES INC (IDXX) Stock Analyst Ratings
USA - NASDAQ:IDXX - US45168D1046 - Common Stock
627.66 USD
-6.7 (-1.06%)
627.66 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 79% to IDXX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 694.47. This target is 10.64% above the current price.
IDXX was analyzed by 21 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about IDXX.
In the previous month the buy percentage consensus was at a similar level.
IDXX was analyzed by 21 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-01 | UBS | Initiate | Neutral |
| 2025-08-15 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-08-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-17 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-07-02 | Stifel | Maintains | Hold -> Hold |
| 2025-06-11 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-05-19 | Stifel | Maintains | Hold -> Hold |
| 2025-05-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-04-14 | Stifel | Maintains | Hold -> Hold |
| 2025-02-10 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-02-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-04 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-01-29 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-12-02 | Leerink Partners | Initiate | Outperform |
| 2024-11-04 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-04 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2024-10-11 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-10 | Stifel | Maintains | Hold -> Hold |
| 2024-08-14 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-07-25 | BTIG | Initiate | Buy |
| 2024-06-24 | Stifel | Maintains | Hold -> Hold |
| 2024-05-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-05-02 | Barclays | Maintains | Overweight -> Overweight |
| 2024-02-06 | Barclays | Maintains | Overweight -> Overweight |
| 2024-02-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-01-30 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-01-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-03 | Goldman Sachs | Maintains | Buy -> Buy |
IDEXX LABORATORIES INC / IDXX FAQ
What is the average price target for IDEXX LABORATORIES INC (IDXX) stock?
21 analysts have analysed IDXX and the average price target is 694.47 USD. This implies a price increase of 10.64% is expected in the next year compared to the current price of 627.66.
How do analysts rate IDEXX LABORATORIES INC (IDXX)?
The consensus rating for IDEXX LABORATORIES INC (IDXX) is 79.0476 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover IDEXX LABORATORIES INC (IDXX) stock?
The number of analysts covering IDEXX LABORATORIES INC (IDXX) is 21.